Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis

[1]  A. Sahebkar,et al.  Statin therapy and plasma free fatty acids: a systematic review and meta-analysis of controlled clinical trials. , 2016, British journal of clinical pharmacology.

[2]  C. Zoccali,et al.  A genetic marker of hyperuricemia predicts cardiovascular events in a meta-analysis of three cohort studies in high risk patients. , 2015, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[3]  A. Sahebkar,et al.  Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials. , 2015, Pharmacological research.

[4]  J. Coombes,et al.  Effects of atorvastatin on oxidative stress in chronic kidney disease , 2015, Nephrology.

[5]  A. Sahebkar,et al.  Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials. , 2015, Progress in lipid research.

[6]  A. Sahebkar,et al.  Association between statin use and plasma D-dimer levels , 2015, Thrombosis and Haemostasis.

[7]  J. Mckenney,et al.  Safety and tolerability of extended-release niacin-laropiprant: Pooled analyses for 11,310 patients in 12 controlled clinical trials. , 2015, Journal of clinical lipidology.

[8]  A. Tsubota,et al.  Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C , 2014, European journal of gastroenterology & hepatology.

[9]  Y. Matsumoto,et al.  Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients. , 2014, Biological & pharmaceutical bulletin.

[10]  M. Matsuzaki,et al.  Impact of intensive lipid lowering on lipid profiles over time and tolerability in stable coronary artery disease: insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). , 2013, Cardiovascular therapeutics.

[11]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[12]  H. Takagi,et al.  Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials. , 2012, International journal of cardiology.

[13]  B. Tomlinson,et al.  Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial , 2011, Scandinavian journal of rheumatology.

[14]  J. Tomassini,et al.  Long‐term efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome , 2010, Diabetes, obesity & metabolism.

[15]  S. Fujimori,et al.  Effects of Three Strong Statins (Atorvastatin, Pitavastatin, and Rosuvastatin) on Serum Uric Acid Levels in Dyslipidemic Patients , 2010, Nucleosides, nucleotides & nucleic acids.

[16]  G. Gensini,et al.  Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: its prognostic role and relation with inflammatory markers: a single center experience. , 2010, International journal of cardiology.

[17]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, PLoS medicine.

[18]  A. Reunanen,et al.  Hyperuricemia as a risk factor for cardiovascular mortality. , 2009, Acta medica Scandinavica. Supplementum.

[19]  Yun-dai Chen,et al.  Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia , 2008, Heart and Vessels.

[20]  D. Mikhailidis,et al.  Targeting vascular risk in patients with metabolic syndrome but without diabetes. , 2005, Metabolism: clinical and experimental.

[21]  L. Niskanen,et al.  Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. , 2004, Archives of internal medicine.

[22]  M. Elisaf,et al.  Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  H. Milionis,et al.  Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. , 2004, American heart journal.

[24]  J. Seeger,et al.  Clinically relevant differences between the statins: implications for therapeutic selection. , 2001, The American journal of medicine.

[25]  C. Stancu,et al.  Statins: mechanism of action and effects , 2001, Journal of cellular and molecular medicine.

[26]  Y. Moriwaki,et al.  Increased visceral fat accumulation further aggravates the risks of insulin resistance in gout. , 2001, Metabolism: clinical and experimental.

[27]  Alex J. Sutton,et al.  Methods for Meta-Analysis in Medical Research , 2000 .

[28]  H. Yamanaka,et al.  Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. , 2000, Journal of epidemiology.

[29]  S Duval,et al.  Trim and Fill: A Simple Funnel‐Plot–Based Method of Testing and Adjusting for Publication Bias in Meta‐Analysis , 2000, Biometrics.

[30]  M. Pahor,et al.  Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. , 1999, Hypertension.

[31]  A. Palomäki,et al.  Enhanced oxidizability of ubiquinol and α‐tocopherol during lovastatin treatment , 1997, FEBS letters.

[32]  Y. Moriwaki,et al.  Impaired lipoprotein metabolism in patients with primary gout--influence of alcohol intake and body weight. , 1994, British journal of rheumatology.

[33]  L. Amorosa,et al.  Fluvastatin with and without niacin for hypercholesterolemia. , 1994, The American journal of cardiology.

[34]  F. Cappuccio,et al.  Uric acid metabolism and tubular sodium handling. Results from a population-based study. , 1993, JAMA.

[35]  A. Sahebkar,et al.  Statin therapy and plasma cortisol concentrations: A systematic review and meta-analysis of randomized placebo-controlled trials. , 2016, Pharmacological research.

[36]  J. Wiliński,et al.  Safety and tolerability of the use of atorvastatin 40 mg in common daily practice in short-term observation in 3,227 patients. , 2013, Przeglad lekarski.

[37]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration , 2013 .

[38]  M. Dimopoulos,et al.  Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. , 2011, Atherosclerosis.

[39]  C. Ballantyne,et al.  Efficacy and safety profile of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemia , 2009 .

[40]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2009, Journal of clinical epidemiology.

[41]  Juan Carlos Espinosa,et al.  Comprehensive Meta-Analysis , 2004 .

[42]  A. Dyer,et al.  Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. , 1989, Journal of clinical epidemiology.